Cagrilintide

Why Researchers Choose Cagrilintide

Cagrilintide is the amylin analogue furthest along in clinical development and the only one with published phase 3 data. It is studied wherever satiety signalling outside the incretin system is the question:

• Amylin and calcitonin receptor pharmacology
• Non-incretin receptor pathways and mechanism comparisons
• Additive-effect research alongside GLP-1 agonists (the CagriSema combination)
• Gastric-emptying and meal-termination studies
• Concentration-response characterisation in published trial ranges

How Cagrilintide Works

Amylin is co-secreted with insulin by pancreatic beta cells and signals through amylin and calcitonin receptor complexes in the area postrema and hypothalamus. Native amylin aggregates readily and clears within minutes, which makes it unusable as a research compound. Cagrilintide is an acylated analogue engineered around both problems: the sequence resists aggregation, and a lipid side chain binds albumin to extend plasma exposure well beyond that of native amylin.

The pathway matters as much as the potency. Amylin receptor signalling operates independently of the GLP-1 receptor, so its effect sits alongside rather than on top of incretin pharmacology. That separation is why the combination with semaglutide is studied as an additive receptor design.

Trial Evidence

Phase 2 monotherapy (Lancet, 2021). In a 26-week dose-finding trial across ten countries, 706 participants received once-weekly cagrilintide between 0.3mg and 4.5mg. 0mg (10.8% vs 9.0%). Gastrointestinal events, mainly nausea, were the most frequent adverse events.

REDEFINE 1 (New England Journal of Medicine, 2025). The phase 3a trial randomised 3,417 adults to cagrilintide 2.4mg plus semaglutide 2.4mg, either compound alone, or placebo over 68 weeks. The combination arm reached a mean body-weight change of -20.4% versus -3.0% on placebo. Gastrointestinal adverse events affected 79.6% of the combination group versus 39.9% on placebo, mostly transient and mild to moderate.

Cagrilintide vs GLP-1 and Multi-Agonist Peptides

Cagrilintide is the compound of interest when the research question concerns amylin signalling itself, or when receptor interaction with the incretin pathway is being modelled. Other long-acting amylin analogues (eloralintide, petrelintide, MET-233i, AZD6234) are in earlier-stage trials, and amycretin combines amylin and GLP-1 activity in a single molecule.

Reconstitution and Storage

Reconstitution: use bacteriostatic water (1 to 2ml per vial); swirl gently until fully dissolved, do not shake. After reconstitution: keep refrigerated (2-8°C), use within 28 days, do not freeze, and protect from direct light.

For research purposes only. Not for human consumption.